The Past, Present, and Future of Fetal Tissue Versus Stem Cell Approach

Authors

• Taz A. Thomas JD, LL.M, PA, University of LynchburgFollow

Specialty

psychiatry and healthcare law

Advisor

Elijah Salzer

Abstract

The evolution of regenerative medicine reflects a critical shift at the intersection of scientific innovation, ethical considerations, and regulatory policy. Although fetal tissue transplantation (FTT) first demonstrated that neural repair was biologically feasible, its long-term clinical potential was constrained by ethical controversy, regulatory instability, and variability in tissue sourcing. These challenges ultimately drove the field toward stem cell transplantation (SCT) as a more sustainable and scalable alternative.

This narrative review examines the factors that contributed to the advancement of SCT and the limited progression of FTT, with particular attention to ethical and regulatory influences on clinical translation. Early FTT studies showed that transplanted neural tissue could survive, integrate, and function in host environments, providing proof of concept for cellular replacement strategies. However, inconsistent outcomes, lack of standardization, and ongoing policy constraints limited broader adoption.

In contrast, SCT—particularly with induced pluripotent stem cell (iPSC) technology—offers improved control over differentiation, greater manufacturing consistency, and fewer sourcing concerns. SCT aligns more closely with current regulatory expectations and provides a clearer pathway to clinical application, although long-term safety and immune compatibility remain important considerations.

Keywords: fetal tissue transplantation, stem cell transplantation, induced pluripotent stem cells, regenerative medicine, ethical and regulatory influences.

Recommended Citation

Thomas TA. The Past, Present, and Future of Fetal Tissue Versus Stem Cell Approach. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2026; 8(1).